Katsumasa Tsurushima
Overview
Explore the profile of Katsumasa Tsurushima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsubaki M, Takeda T, Matsuda T, Kishimoto K, Tanaka R, Tsurushima K, et al.
Clin Exp Med
. 2022 Nov;
23(5):1597-1607.
PMID: 36451049
Multiple myeloma (MM) frequently acquires multidrug resistance (MDR), which is due to poor prognosis. Our previous study indicated that high expression of Survivin and multidrug resistance protein 1 (MDR1) and...
2.
Tsurushima K, Tsubaki M, Takeda T, Matsuda T, Kimura A, Takefuji H, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955813
Triple-negative breast cancer (TNBC) has the poorest prognosis of all breast cancer subtypes. Recently, the activation of NF-κB, which is involved in the growth and survival of malignant tumors, has...
3.
Tsurushima K, Yanagishita Y, Ogawa N, Fujii C, Yasui Y, Takeda T, et al.
Gan To Kagaku Ryoho
. 2022 Jul;
49(6):701-704.
PMID: 35799400
Olanzapine(OLZ)is a multi-acting receptor-targeted antipsychotic drug approved in Japan in December 2017 for the treatment of anticancer drug-induced nausea and vomiting. However, the recommended doses and administration periods of OLZ...
4.
Tsubaki M, Takeda T, Matsuda T, Yamamoto Y, Higashinaka A, Yamamoto K, et al.
Cytokine
. 2021 May;
144:155591.
PMID: 34052656
Interleukin 19 (IL-19) is a member of the IL-10 family of cytokines and is known as an inhibitory cytokine. IL-10, also an inhibitory cytokine, suppresses the receptor activator of nuclear...
5.
Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, et al.
Biomedicines
. 2021 Jan;
9(1).
PMID: 33406639
Multiple myeloma (MM) is an incurable malignancy often associated with primary and acquired resistance to therapeutic agents, such as proteasome inhibitors. However, the mechanisms underlying the proteasome inhibitor resistance are...
6.
Kato N, Tateishi K, Tsubaki M, Takeda T, Matsumoto M, Tsurushima K, et al.
Pharmaceuticals (Basel)
. 2021 Jan;
14(1).
PMID: 33396362
Chemotherapy-induced peripheral neuropathy is a common factor in limiting therapy which can result in therapy cessation or dose reduction. Gabapentin, a calcium channel inhibitor, and duloxetine, a serotonin noradrenaline reuptake...
7.
Tabata M, Tsubaki M, Takeda T, Tateishi K, Tsurushima K, Imano M, et al.
BMC Complement Med Ther
. 2020 Mar;
20(1):84.
PMID: 32171300
Background: Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required...
8.
Tabata M, Tsubaki M, Takeda T, Tateishi K, Maekawa S, Tsurushima K, et al.
Clin Exp Med
. 2019 Oct;
20(1):63-71.
PMID: 31650359
Multiple myeloma (MM) is the second most common hematologic malignancy. In spite of the development of new therapeutic agents, MM remains incurable due to multidrug resistance (MDR) and the 5-year...